Initial clinical studies reported that use of brequinar to inhibit DHODH activity in patients with advanced breast cancer has a moderate favorable impact [228] while a number of more recent preclinical studies suggest that combined DHODH and MEK inhibition may have the potential to overcome chemotherapy resistance [226,229]. The gene discussed is DHODH; the disease is breast carcinoma.